BCL-2 and BCL-XL were inhibited by the use of navitoclax (ABT-263) in hepatocellular carcinoma (HCC) cells, however, MCL-1 mRNA and protein were stabilized, resulting in a limited effect (Wang et al. 2014). The gene discussed is BCL2L1; the disease is hepatocellular carcinoma.